<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02715570</url>
  </required_header>
  <id_info>
    <org_study_id>PC_ASP_001</org_study_id>
    <secondary_id>2015-003327-64</secondary_id>
    <nct_id>NCT02715570</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945</brief_title>
  <official_title>A Randomised, Single-blind, Placebo-controlled, Study to Assess the Safety and Tolerability of Single Escalating and Repeat, Inhaled Doses of PC945 in Healthy Subjects Combined With a Randomised, Single-blind, Placebo-controlled, Parallel Group to Assess the Safety and Tolerability of a Single Dose of Inhaled PC945 in Subjects With Mild Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pulmocide Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pulmocide Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PC945 is a new medicine being developed for treatment of fungal lung diseases. The main&#xD;
      purpose of this study is to investigate the safety, tolerability and pharmacokinetics of&#xD;
      single and repeat doses of PC945&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2017</start_date>
  <completion_date type="Actual">April 27, 2018</completion_date>
  <primary_completion_date type="Actual">April 27, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks</time_frame>
    <description>Assessment of number of adverse events reported by subjects following dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead ECG assessment</measure>
    <time_frame>Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks</time_frame>
    <description>Change from pre-dose values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs assessment (blood pressure and heart rate - measured together)</measure>
    <time_frame>Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks</time_frame>
    <description>Change for pre-dose values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory assessments (blood and urine samples - measured together)</measure>
    <time_frame>Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks</time_frame>
    <description>Change from pre-dose values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spirometry assessment (FEV1 &amp; FVC - measured together)</measure>
    <time_frame>Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks</time_frame>
    <description>Change from pre-dose values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration data of PC945</measure>
    <time_frame>Cohort 1 (4 treatment periods) &amp; Cohort 3 (1 treatment period) Day1 = 8 samples; Day2 = 2 samples; Day3 = 1 sample; F/U = 1 sample. Cohort 2 - Days1&amp;7 = 10 samples; Days2,5,6 = 1 sample; Day8 = 2 samples; Day9 = 1 sample; F/U = 1 sample</time_frame>
    <description>Blood levels of PC945 measured after dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry assessment (FEV1)</measure>
    <time_frame>Cohort 3 only - Day 1, 8 hours</time_frame>
    <description>Observed drops in FEV1 assessment after dosing patients with mild asthma</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Determination of exogenous fungal flora</measure>
    <time_frame>Cohort 1 (4 treatment periods) &amp; Cohort 3 (1 treatment period) Day1 = 1 sample; Day3 = 1 sample. Cohort 2, Day 1 = 1 sample; Day 9 = 1 sample</time_frame>
    <description>Assessment of fungal flora found in mouth and throat after dosing</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Aspergillosis</condition>
  <arm_group>
    <arm_group_label>Single dose - healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Repeat dose - healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose - asthmatic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PC945 - single doses</intervention_name>
    <description>Safety and tolerability of single doses</description>
    <arm_group_label>Single dose - asthmatic patients</arm_group_label>
    <arm_group_label>Single dose - healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - single doses</intervention_name>
    <description>Safety and tolerability of single doses</description>
    <arm_group_label>Single dose - asthmatic patients</arm_group_label>
    <arm_group_label>Single dose - healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PC945 - repeat doses</intervention_name>
    <description>Safety and tolerability of repeat doses</description>
    <arm_group_label>Repeat dose - healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - repeat doses</intervention_name>
    <description>Safety and tolerability of repeat doses</description>
    <arm_group_label>Repeat dose - healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All subjects (Cohorts 1, 2 &amp; 3)&#xD;
&#xD;
          -  Male or female, aged between 18 and 65 years inclusive (at the time of consent) who&#xD;
             fit one of the following criteria: Women of childbearing potential who are willing and&#xD;
             able to use required contraception from screening until 30 days after receipt of the&#xD;
             final dose; Women of non-childbearing potential defined as being amenorrhoeic or have&#xD;
             been permanently sterilised; Men who are willing and able to use required&#xD;
             contraception from the time of the first dose, until 90 days after receipt of the&#xD;
             final dose of study medication.&#xD;
&#xD;
          -  Females with a negative pregnancy test at screening and at Day -1.&#xD;
&#xD;
          -  Willing and able to adhere to the restrictions and prohibitions required by this&#xD;
             protocol.&#xD;
&#xD;
          -  Signed informed consent form.&#xD;
&#xD;
          -  Body weight ≥ 50 kg and body mass index (BMI) within the range 18 - 30 kg/m2&#xD;
             (inclusive).&#xD;
&#xD;
          -  Average QTcF &lt;450 msec at screening and pre-dose.&#xD;
&#xD;
          -  Vital signs assessments within normal ranges&#xD;
&#xD;
        Healthy Subjects (Cohorts 1 and 2)&#xD;
&#xD;
          -  Healthy as determined by a physician based on a full medical examination.&#xD;
&#xD;
          -  Spirometry readings (FEV1 and FVC) to be ≥ 80% of predicted value and FEV1/FVC ratio &gt;&#xD;
             0.7 at screening.&#xD;
&#xD;
        Subjects with Asthma (Cohort 3)&#xD;
&#xD;
          -  Diagnosis of asthma.&#xD;
&#xD;
          -  Positive result to methacholine challenge at the screening visit.&#xD;
&#xD;
          -  FEV1 &gt;60% of predicted normal value at screening.&#xD;
&#xD;
          -  Stable asthma based on physician assessment at screening, with no changes of therapy&#xD;
             in the 12 weeks prior to screening and no hospitalization or visit to accident and&#xD;
             emergency for asthma in the 12 months prior to screening&#xD;
&#xD;
          -  Otherwise healthy on the basis of a full medical examination at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All subjects (Cohorts 1, 2 &amp; 3)&#xD;
&#xD;
          -  Any acute illness.&#xD;
&#xD;
          -  Upper or lower respiratory tract infection within 4 weeks of the screening visit or&#xD;
             randomisation.&#xD;
&#xD;
          -  Use of prescription medications within 14 days of the Screening visit.&#xD;
&#xD;
          -  Taking over the counter (OTC) medications other than vitamins or multivitamins, within&#xD;
             14 days prior to Screening.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study with average&#xD;
             weekly intake of &gt;21 units for males, or &gt;14 units for females.&#xD;
&#xD;
          -  History of drug or alcohol abuse within the previous 5 years.&#xD;
&#xD;
          -  Smoker (regular or irregular), or has smoked or used nicotine-containing products&#xD;
             (including e-cigarettes) within the 6 months prior to screening or has a smoking&#xD;
             history of ≥ 10 pack years.&#xD;
&#xD;
          -  Positive test for HIV-1 &amp; -2 antibodies at screening.&#xD;
&#xD;
          -  Positive pre-study hepatitis B surface antigen or positive hepatitis C antibody result&#xD;
             at screening.&#xD;
&#xD;
          -  Positive test for alcohol, smoking or drugs of abuse at screening or Day -1.&#xD;
&#xD;
          -  Received an experimental drug or used an experimental medical device within last 3&#xD;
             months.&#xD;
&#xD;
          -  Allergy to any of the active or inactive ingredients in the study medication.&#xD;
&#xD;
          -  Donation of blood in excess of 500 mL within a 3 month period prior to dosing, or if&#xD;
             study participation would result in blood loss in excess of 500 mL in a 3 month&#xD;
             period.&#xD;
&#xD;
          -  Mentally or legally incapacitated.&#xD;
&#xD;
          -  An employee of the Sponsor or contract research organisation (CRO), or a relative of&#xD;
             an employee of the Sponsor or CRO.&#xD;
&#xD;
          -  Unable or unwilling to undergo multiple venepuncture procedures or poor access to&#xD;
             veins suitable for cannulation.&#xD;
&#xD;
          -  Pregnant or lactating female&#xD;
&#xD;
        Healthy subjects (Cohorts 1 and 2)&#xD;
&#xD;
          -  Any chronic illness or clinically relevant abnormality identified on the screening&#xD;
             medical assessment, laboratory tests or ECG.&#xD;
&#xD;
        Subjects with asthma (Cohort 3)&#xD;
&#xD;
          -  Had an episode of life-threatening asthma.&#xD;
&#xD;
          -  Presence of clinically significant diseases other than asthma, hyper-responsive&#xD;
             airways, seasonal allergic rhinitis or atopic diseases.&#xD;
&#xD;
          -  Experienced an acute asthma exacerbation in the 12 months prior to screening requiring&#xD;
             hospitalisation or accident and emergency treatment or management with systemic or&#xD;
             injectable steroids.&#xD;
&#xD;
          -  Uncontrolled, or moderate to severe asthma based on PI assessment and/or use of&#xD;
             prohibited medications, or has required treatment with these therapies in the previous&#xD;
             12 weeks.&#xD;
&#xD;
          -  History or presence of any known conditions contraindicated for methacholine&#xD;
             challenge.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muna Albayaty, MBChB, FFPM, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>cro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel EPCU</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>March 16, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2016</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aspergillus species</keyword>
  <keyword>Filamentous fungi</keyword>
  <keyword>14-alpha Demethylase Inhibitors</keyword>
  <keyword>Anti-Infective Agents</keyword>
  <keyword>Antifungal Agents</keyword>
  <keyword>Enzyme Inhibitors</keyword>
  <keyword>Aspergillosis</keyword>
  <keyword>Allergic Bronchopulmonary</keyword>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

